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Childhood craniopharyngiomas are rare embryogenic malformations of the sellar region, presumably derived from Rathke cleft
epithelium. The overall survival rates after neurosurgical intervention and/or irradiation are high (92%). However, the quality of
survival is frequently impaired due to endocrine deﬁciencies, sleep disturbances, daytime sleepiness, and severe obesity caused
by hypothalamic lesions. Based on self-assessment using nutritional diaries, caloric intake was similar in patients and BMI-
matched controls. Analyses of physical activity by accelerometric measurements showed a markedly lower level of physical
activity. Signiﬁcant daytime sleepiness and disturbances of circadian rhythms have been demonstrated in obese childhood
craniopharyngioma patients. Daytime sleepiness and obesity in these patients were both correlated with low nocturnal and
early morning melatonin levels. Polysomnographic studies in patients with severe daytime sleepiness revealed sleeping patterns
typical for secondary narcolepsy. Reports on a beneﬁcial eﬀect of treatment with central stimulating agents supported the
hypothesis that secondary narcolepsy should be considered as a rare cause for severe daytime sleepiness in patients with childhood
craniopharyngioma.
Craniopharyngiomas are embryogenic malformations of
low histological malignancy (WHO I◦), which arise from
ectoblastic remnants of Rathke’s pouch and can be found
anywhere along the path of development of Rathke’s pouch
in hypothalamic and pituitary regions, both of importance
in endocrine regulation and satiety modulation [1]. Cran-
iopharyngiomas are the most common intracranial tumors
of nonglial origin in the pediatric population, constituting
between 1.2 to 4% of all brain tumors and 6 to 9% of
pediatric brain tumors. Overall there are 0.5 to 2 new cases
per million population occurring each year, 30 to 50% of
which are children and adolescents [2]. The peak incidence
is at age 5 to 10 years, but they can occur at any age including
infancy and pre- and neonatal period [3].
Whereas the childhood form of craniopharyngioma
mainly presents with an adamantinous histology, the adult
type of craniopharyngioma occurs at a peak age of 50–75
years and presents mainly with papillary histology. Other
tumors with similar localization but diﬀerent characteristics
onmagneticresonanceimaging(MRI)aregerminoma,germ
cell tumours, langerhans cell histiocytosis, and pilocytic
astrocytoma [6].
Headaches, visual disturbances, polyuria, reduced
growth rates, and weight gain are frequently the ﬁrst
symptoms in the history of patients with childhood
craniopharyngioma [7, 8]. The clinical features at the time
of diagnosis of craniopharyngioma during childhood are
usually unspeciﬁc signs of increased intracranial pressure.
Major symptoms are headaches, impaired vision (62–84%,
primarily in adults), and endocrine failures (52–87%,
primarily in children). Chiasmatic involvement may be
attended by defects of vision and visual ﬁelds. Endocrine
deﬁciencies aﬀect the hypothalamic-pituitary axes for
growth hormone (75%), gonadotrophins (40%), ACTH2 International Journal of Endocrinology
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Figure 1: Obesity and daytime sleepiness in relation to the localization of craniopharyngioma. The patient whose preoperative MRI (a)
showed a large tumor extending to the suprasellar region and inﬁltrating the hypothalamus developed severe daytime sleepiness and,
consequently, obesity (BMI: +14 SD [4]). The patient with a childhood craniopharyngioma of intrasellar localization seen in Figure 1(b)
maintained normal weight (BMI: +1 SD [4]) and developed no daytime sleepiness.



































































































Figure 2: Salivary melatonin concentrations at nighttime (a) and in the morning (b) in patients with childhood craniopharyngioma,
hypothalamic pilocytic astrocytoma, and controls in relation to the degree of obesity (body mass index [BMI] <2S D[ ﬁ l l e db l a c kb o x e s ] ,
BMI 2–4 SD [hatched gray boxes], or BMI ≥ 4 SD [open boxes]). The horizontal line in the middle of the box depicts the median. Edges
of the box mark the 25th and 75th percentile. Whiskers indicate the range of values that fall within 1.5 boxlengths. Values more than 1.5
box-length from the 25th and 75th percentiles are marked by an asterix. (Modiﬁed from [5], with the kind permission of Endocrine Press.)
(25%), and thyroid-stimulating hormone (TSH) (25%).
17% of the children with craniopharyngioma present with
diabetes insipidus prior to surgery [9].
The therapeutic goal is ﬁrst to relieve symptoms by
urgent surgical decompression and second to achieve an
early long-term cure by complete resection but without
causing further damage to the hypothalamus or optic tract.
Postoperative sequelae are deemed unacceptable in patients
with preoperatively intact function. However, the optimal
primary therapeutic strategy to achieve the correct balance
between late sequelae and successful cure remains unknown.
Even after complete surgical resection, craniopharyngiomaInternational Journal of Endocrinology 3
relapses occur in up to 17% of patients [10]. With radical
resection, the risk of hypothalamic damage is considerable,
especially in craniopharyngioma with suprasellar extension
to the hypothalamic area. The appropriate time point of
irradiation in patients with residual tumor after incomplete
resection is controversial as well [10–13].
Although the tumor itself is low-grade histological
malignancy and the overall survival rate (92%) of patients
is high [9], there is considerable morbidity even when the
tumor can be completely resected [5, 7, 9, 10, 14–24].
Childhood craniopharyngioma patientsoftensuﬀersequelae
ofsevereobesity. Increasedbody weightin patients atrisk for
the development of severe obesity during followup is already
detectable at the time of diagnosis of craniopharyngioma
[15]. Patients who developed severe obesity presented with
a higher body mass index SDS [4] already at the time
of diagnosis when compared with patients who kept their
normal weight. The evaluation of the patients’ history [7]
and anthropometric data collected before diagnosis [15]
conﬁrmed the observation, that pathogenic mechanisms for
the development of later obesity have signiﬁcant impact on
weight already at the time of diagnosis before initiation of
therapy. Hypothalamic involvement of craniopharyngioma
is the most important risk factor for the development of
obesity before and after tumor diagnosis (Figure 1)[ 9, 10,
15–17, 19, 25].
In spite of hormonal substitution, the management of
hypothalamic injury-induced hyperphagia is diﬃcult and
severeobesityoccurspostoperativelyinupto52%ofpatients
with at least one half of these patients having extreme
diﬃculty controlling their desire to eat [9, 24]. Severe
obesity has major negative impact on quality of life in
survivors of childhood craniopharyngioma [8, 10, 14, 16,
17, 19, 24]. Conventional strategies for weight control are
less eﬃcient because of impaired physical activity due to
attendant neurological and visual deﬁcits and the complaint
of increased daytime sleepiness.
A German multicenter study on childhood cranio-
pharyngioma patients suggested a secondary hypothalamic
disorder as pathogenic factor in patients at risk for severe
obesity and increased daytime sleepiness [9]. M¨ uller et
al. surveyed a large group of patients with childhood
craniopharyngioma and hypothalamic astrocytoma for day-
time sleepiness using the German version of the Epworth
Sleepiness Scale (ESS) [26]. About 1/3 of the patients
reported increased daytime sleepiness, characterized by an
ESS score above 10. The severity of their daytime sleepiness
was unexpectedly high, especially in obese patients with a
BMI > 4S D[ 4].
Sleep regulation and circadian rhythms are at least
partially mediated by hypothalamic structures, for example,
the suprachiasmatic nucleus, regulating melatonin secretion
[27]. The secretion of melatonin, a pineal indoleamine,
occurs during hours of darkness and as it aﬀects sleep
patterns it has been tried in treating jet lag and other
disorders from delay of sleep because of its possible role
in inﬂuencing circadian rhythm. Because a destruction or
dysfunction of the suprachiasmatic nucleus seems likely in
many craniopharyngioma patients with suprasellar tumor
extension [28], M¨ uller et al. compared melatonin secretion
in severely obese, obese, and in nonobese craniopharyn-
gioma patients [5]. To analyze the inﬂuence of obesity and
hypothalamic lesions on melatonin secretion, patients with
hypothalamic tumors (pilocytic astrocytomas) and obese
and normal weight control subjects were also analyzed.
The authors compared salivary melatonin concentrations at
morning, midday, evening, and nighttime among severely
obese, obese, and nonobese patients and normal controls.
Salivary melatonin concentrations correlate with melatonin
concentrations in plasma [29, 30].
Whereas several studies [31–33]o nd i ﬀerent patient
cohorts have found no signiﬁcant relation between mela-
tonin secretion and obesity, Birketvedt et al. [34]r e p o r t e d
on a rare night eating syndrome characterized by fre-
quent awakening at night, higher nocturnal energy intake,
and attenuation of nocturnal rise in plasma melatonin.
As hypothesized based on hypothalamic disorders in the
severely obese craniopharyngioma patients, decreased mela-
tonin concentrations at nighttime were detected in patients
analyzedbyM¨ ulleretal.[5](Figures2(a),2(b)).Theauthors
speculated that the diurnal rhythm of melatonin was sup-
pressed in obese patients with hypothalamic tumors as cran-
iopharyngioma or pilocytic astrocytoma. As cortisol may
also inﬂuence wakefulness, salivary cortisol concentrations
were compared in all groups to exclude confounding eﬀects.
No diﬀerences for cortisol serum concentrations were found
among the groups. The signiﬁcant negative correlations
between salivary melatonin concentrations in the morning
and at nighttime and the ESS scores indicate that reduced
nocturnalmelatoninsecretionmayleadtoincreaseddaytime
sleepiness in patients with childhood craniopharyngioma.
The ﬁndings suggested that increased daytime sleepiness in
patients with childhood craniopharyngioma was associated
with decreased nocturnal melatonin levels, which were
related to the degree of obesity and the tumor diagnosis.
First promising experiences on experimental substitution
of melatonin in obese patients with craniopharyngioma
supported the hypothesis that increased daytime sleepiness
is associated with reduced nocturnal melatonin secretion
[20].
The observations conﬁrmed previous reports on agede-
pendency of melatonin secretion [35]. However, in spite
of the fact that age-dependent eﬀects were found sim-
ilarly in all analyzed subgroups and the agedependency
had no statistical impact on reported diﬀerences in terms
of craniopharyngioma-associated melatonin depression, it
has to be stated that the preliminary results have to be
conﬁrmed by prospective analysis of larger cohorts with
more homogeneous agedistribution. Further studies on the
hypothesis are part of the German prospective multicenter
studyKRANIOPHARYNGEOM2007onpatientswithchild-
hood craniopharyngioma [10, 36]. As it has been reported
[9] that hypothalamic damage is a risk factor for severe
obesity in craniopharyngioma patients, it can be speculated
that hypothalamic damage could have been responsible for
disturbances in melatonin secretion. This speculation is
supported by similar ﬁndings for patients with hypothalamic
tumors of other histology such as pilocytic astrocytoma [5].4 International Journal of Endocrinology
Studies on physical activity using accelerometric analysis
of movement counts revealed that physical activity was
reduced in the group of craniopharyngioma patients with
obesity and hypothalamic involvement when compared with
age and BMI-matched controls [25]. Caloric intake was sim-
ilar in normal controls (1027 healthy nonobese subjects, rep-
resentativesampleofthe7to16year-oldGermanpopulation
with an age distribution: 11.3±2.7 years) and craniopharyn-
giomapatients(27patients,agedistribution:11.7±2.6y ears)
and had no signiﬁcant impact on the degree of obesity and
the physical activity in analyzed cohorts [25]. Hypothalamic
involvement of craniopharyngioma had major negative
impact on functional capacity and quality of life and was a
major risk factor for the development of severe obesity in
survivors of childhood craniopharyngioma [5, 7–10, 14–21].
Reports [5, 22, 25] on increased daytime sleepiness and
reduced physical activity in patients with craniopharyn-
gioma support the hypothesis that physical activity might be
decreased in these patients due to yet unknown neuroen-
docrine disorders. On the other hand, sleep at night was
severely disturbed in many patients with increased daytime
sleepiness [5]. Accordingly, M¨ uller et al. analyzed daytime
sleepiness and polysomnographic patterns in patients with
childhood craniopharyngioma in order to deﬁne further risk
factors for severe obesity.
Since sleep regulation and circadian rhythms are at least
partially mediated by hypothalamic structures, for example,
the suprachiasmatic nucleus, M¨ uller et al. conducted a
two-night polysomnography (PSG) and a multiple sleep
latency test (MSLT) consisting of four or ﬁve 20-minute
naps with nine obese craniopharyngioma patients and one
patient with an astrocytoma of the pituitary stalk displaying
acute daytime sleepiness [20]. The MSLT was developed
to render a better diagnostic sensitivity and speciﬁcity in
the diagnosis, and usually two or more SOREMP in the
MSLT are regarded as necessary for the diagnosis. Usually
a mean sleep latency of <5 minutes should be observed
for the diagnosis of narcolepsy. The diagnostic validity of
MSLTinearlyinfancyiscontroversial.However,theyoungest
patient included in our MSLT analyses was 10 years of age
[20]. Only two patients showed an obstructive sleep apnea
syndrome (OSAS), the usual sleep-related disorder in acutely
obese patients. However, seven patients fulﬁlled the classic
PSG criteria for secondary narcolepsy or hypersomnia.
These results were unexpected since none of the patients
complained of cataplexy, hypnagogic hallucinations, or sleep
paralysis on inquiry. What is particularly noteworthy is that
recent research has suggested a hypothalamic disorder in
narcolepsy. A defect in the orexin II receptor is responsible
for canine narcolepsy [37] and orexin knockout mice
show characteristic features of narcolepsy [38]. Orexin is
expressed exclusively in the lateral hypothalamus, and the
orexin receptors seem to be wider spread [39]. In human
narcoleptics, 8 of 10 had orexin A below the detection limit
of the assay used [40]. Despite excessive research in this ﬁeld,
only one patient could be identiﬁed with a genetic defect in
the orexin system [41]. In autopsy of narcoleptic patients,
the lack of orexin neurons in the lateral hypothalamus was
observed in 10 cases [41, 42].
It has also been reported that systemic administra-
tion of orexin relieves narcoleptic symptoms in dogs [43,
44]. The peculiar ﬁnding that sleep and sleep attacks in
narcoleptic patients are initiated by a sleep onset REM
period (SOREMP) was recognized in the early 1960s [45].
Since then, this PSG ﬁnding is regarded as a phenomenon
occurring almost exclusive in narcolepsy, although there are
some descriptions of SOREM in subjects without narcolepsy.
Garc´ ıa-Borreguero et al. [46] reported that glucocorticoid
replacement therapy in Addison’s patients was permissive for
decreased REM latency when hydrocortisone was taken at
bedtime. MSLT was not performed in this study. All patients
with SOREM were under treatment with hydrocortisone
replacement therapy in the study of M¨ uller et al. [20]. How-
ever, hydrocortisone replacement treatment alone cannot
explain the excessive daytime sleepiness in analyzed patients
asthisisstandardtreatmentforcraniopharyngiomapatients,
including those not suﬀering severe daytime sleepiness.
Secondary narcolepsy is a rare disorder. However, several
case reports were published on secondary narcolepsy, mainly
reporting on patients with tumorous conditions in the
hypothalamic area [47, 48]. Diagnostic criteria vary, but all
patients presented with hypersomnia as a leading pathology.
Interestingly, the majority of reported patients show hyper-
somnia, but not cataplexy, hallucinations, or sleep paralysis.
In fact, a medline search yielded over 30 cases of secondary
narcolepsy without cataplexy during the last 50 years, but
yielded only 13 cases with secondary cataplexy. These cases
are surprisingly very heterogenic and only two cases had
tumors in the area of the hypothalamus [49], two cases had
tumors in the brain stem pontomedullary astrocytoma [50],
glioblastoma of rostral brain stem [51], one patient had a
frontal lobe tumor [52], ﬁve patients had meningioma [53],
and ﬁve patients had meningeal carcinomatosis [54].
Not all patients with a tumorous condition in the
hypothalamic area suﬀer from hypersomnia, and even less
from cataplexy. This is surprising, since deﬁciency of orexin
is regarded as the cause of hypersomnia and cataplexy in
idiopathic narcolepsy. Cases with secondary cataplexy in the
literature seem to have more widespread tumor disease than
cases with secondary hypersomnia. This leads to speculation
that there must be some other pathology operating in addi-
tion to orexin deﬁciency to produce cataplexy in idiopathic
narcolepsy. This hypothesis is supported by the fact that
some patients with clear idiopathic narcolepsy and cataplexy
have normal orexin levels in cerebrospinal ﬂuid [40].
In concert with ﬁndings [5, 20] suggesting that increased
daytime sleepiness is a common complaint in patients
with childhood craniopharyngioma and that the incidence
seems to be equal in obese and normal weight patients,
reported results [22] together with current research on
narcolepsy lead to the conclusion that secondary hypersom-
nia and secondary narcolepsy may be contributing causes
for increased daytime sleepiness and weight control diﬃ-
culties in obese craniopharyngioma patients. Preliminary
positiveexperienceswithcentralstimulating agenttreatment
(Modaﬁnil or Methylphenidate) in patients with childhood
craniopharyngioma and secondary narcolepsy support this
speculation [22, 55].International Journal of Endocrinology 5
Based on the literature [56, 57], radical surgery with
potential damage to hypothalamic structures and consec-
utive increased daytime sleepiness is no appropriate treat-
ment strategy in patients with hypothalamic involvement
of childhood craniopharyngioma. For such patients inno-
vative treatment strategies are warranted after incomplete
resection. Accordingly, in KRANIOPHARYNGEOM 2007
quality of life, event-free survival and overall survival rates
in patients (age ≥5 years at diagnosis and at incomplete
resection) are currently analyzed after randomization of
the time point of irradiation after incomplete resection
(immediate irradiation versus irradiation at progression of
residual tumor). The schedule of prospective data collection
and the set and deﬁnition of parameters is based on a
European consensus [13]. Standardized European data sets
on a rare disease such as childhood craniopharyngioma
should help to increase cohort sizes and facilitate common
data evaluation [10]. Hopefully, this international study
will lead to treatment recommendations that prevent severe
sequelae such as increased daytime sleepiness and secondary
narcolepsy in patients with childhood craniopharyngioma.
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